Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

86
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
86
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

10
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
10
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

645
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
645
Cancer Therapies02:49

Cancer Therapies

7.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.8K
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

41
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
41
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

13
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
13

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Multipart Phase 1 Study to Assess Safety and Pharmacokinetics of Ibuzatrelvir in Healthy Participants and Dose Selection for a Dose-Ranging Study.

Clinical and translational science·2026
Same author

Point-of-Care Nucleic Acid Amplification Tests for Respiratory Syncytial Virus Detection in Children and Adults: A Systematic Literature Review.

Infectious diseases and therapy·2026
Same author

Discovery of an ITK and TRK kinase inhibitor for the potential topical treatment of atopic dermatitis.

Nature communications·2026
Same author

Vaccines against antimicrobial resistance.

Philosophical transactions of the Royal Society of London. Series B, Biological sciences·2026
Same author

Vaccines and antimicrobial resistance: from science to policy-summary and outcomes.

Philosophical transactions of the Royal Society of London. Series B, Biological sciences·2026
Same author

Safety and Pharmacokinetics of the RSV Fusion Inhibitor Sisunatovir Across Two Early-phase Studies in Infants and Children With RSV Lower Respiratory Tract Infection.

The Pediatric infectious disease journal·2026

Related Experiment Video

Updated: Jul 31, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
08:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

2.8K

Therapeutics for COVID-19.

Sima S Toussi1, Jennifer L Hammond2, Brian S Gerstenberger3

  • 1Pfizer, Pearl River, NY, USA.

Nature Microbiology
|May 4, 2023
PubMed
Summary
This summary is machine-generated.

Antiviral therapies for coronavirus disease 2019 (COVID-19) are crucial for unvaccinated and immunocompromised individuals. Nirmatrelvir-ritonavir and molnupiravir show promise in reducing severe outcomes, though challenges remain for developing new antiviral drugs.

More Related Videos

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

30.3K
Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses
03:53

Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses

Published on: November 10, 2023

1.3K

Related Experiment Videos

Last Updated: Jul 31, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
08:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

2.8K
Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

30.3K
Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses
03:53

Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses

Published on: November 10, 2023

1.3K

Area of Science:

  • * Virology
  • * Infectious Diseases
  • * Pharmacology

Background:

  • * Vaccines and monoclonal antibodies were developed rapidly for COVID-19 prevention.
  • * A significant need persists for effective therapeutics in non-vaccinated, immunocompromised, or waning immunity populations.
  • * Early investigational therapies demonstrated mixed efficacy, highlighting the need for robust treatment options.

Purpose of the Study:

  • * To review the development of therapeutic agents for treating COVID-19.
  • * To discuss the efficacy and limitations of various antiviral and immunomodulatory treatments.
  • * To identify ongoing challenges in the development of novel anticoronavirals.

Main Methods:

  • * Review of clinical trial data for investigational COVID-19 therapies.
  • * Analysis of repurposed drugs, including nucleoside inhibitors and protease inhibitors.
  • * Examination of immunomodulatory agents targeting host responses.

Main Results:

  • * AT-527 showed viral load reduction in hospitalized patients but not outpatients.
  • * Molnupiravir reduced mortality but did not prevent hospitalization.
  • * Nirmatrelvir-ritonavir significantly reduced hospitalization and death, receiving Emergency Use Authorization.
  • * Immunomodulatory drugs like baricitinib and tocilizumab are utilized for symptom management.

Conclusions:

  • * Nirmatrelvir-ritonavir and molnupiravir represent key advancements in COVID-19 treatment.
  • * Continued research is essential to overcome challenges in developing broadly effective and accessible antiviral therapies.
  • * A combination of antiviral and immunomodulatory strategies may be necessary for comprehensive COVID-19 management.